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CONSPECTUS
O
ver hundreds of millions of years, animals have evolved endogenous lipoprotein nanoparticles for shuttling hydrophobic
molecules to different parts of the body. In the last 70 years, scientists have developed an understanding of lipoprotein
function, ofteninrelationshiptolipidtransport andheartdisease.Suchbiocompatible, lipid proteincomplexesare alsoideal for
loading and delivering cancer therapeutic and diagnostic agents, which means that lipoprotein and lipoprotein-inspired
nanoparticles also offer opportunities for cancer theranostics. By mimicking the endogenous shape and structure of lipoproteins,
the nanocarrier can remain in circulation for an extended period of time, while largely evading the reticuloendothelial cells in the
body's defenses. The small size (less than 30 nm) of the low-density (LDL) and high-density (HDL) classes of lipoproteins allows
them to maneuver deeply into tumors. Furthermore, lipoproteins can be targeted to their endogenous receptors, when those are
implicated in cancer, or to other cancer receptors.
InthisAccount, we review the field oflipoprotein-inspired nanoparticles relatedto the delivery ofcancer imaging and therapy
agents. LDL has innate cancer targeting potential and has been used to incorporate diverse hydrophobic molecules and deliver
themtotumors.Nature'smethodofreroutingLDLinatherosclerosisprovidesastrategytoextendthecancertargetingpotentialof
lipoproteins beyond itsnarrow purview. Although LDL hasshown promise as a drug nanocarrier for cancer imaging andtherapy,
increasingevidenceindicatesthatHDL,thesmallestlipoprotein,mayalsobeofusefordrugtargetinganduptakeintocancercells.
WealsodiscusshowsyntheticHDL-likenanoparticles,whichdonotincludehumanorrecombinantproteins,candelivermolecules
directlytothecytoplasmofcertaincancercells,effectivelybypassingtheendosomalcompartment. ThisstrategycouldallowHDL-
likenanoparticlestobeusedtodeliverdrugsthathaveincreasedactivityinthecytoplasm.Lipoproteinnanoparticleshaveevolved
to be ideal delivery vehicles, and because of that specialized function, they have the potential to improve cancer theranostics.
Introduction
Current diagnosis and treatment options for many cancers
must be improved, despite significant advances over the
pastdecades.Extensivepreclinicalresearchincancernano-
technology holds much further potential to generate
improved options for diagnosing and treating the disease.
There areseveralfeatures ofnanoparticlesthat makethem
suited for both diagnosis and therapy. One central advan-
tage of therapeutic nanoparticles is the concept of high
payload incorporation (i.e., drug) into a nanoparticle. In
carrying a large payload, nanocarriers can favorably mod-
ulate biodistribution and pharmacokinetic profiles of the1106 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 1105–1113 ’ 2011 ’ Vol. 44, No. 10
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drug formulations. Another advantage of most nanoparti-
cles is their multimodal loading capability. The surface or
coreofthenanoparticlemaybeloadedwithmultipleagents,
so that treatment and imaging of treatment can occur
simultaneously. Chelators may be included for radioiso-
topes for PET/SPECT imaging and other metals for CT and
MRI in vivo imaging. Thus, this presents a new opportunity
for monitoring drug distribution. While tritiated drugs have
been used to monitor biodistribution of small molecule
drugs, using these for routine treatment has not been
practical. Since nanoparticles have the capacity to be accu-
rately tracked in vivo, this opens up many new avenues for
nanomedicine. For instance, drug biodistribution could be
monitored on a patient by patient basis to determine
whether drug accumulation is sufficient for a therapeutic
effect. Preclinical nanomedicine research is already firmly
entrenched in combined imaging and therapy, and as imag-
ing modalities improve, so will the monitoring methods. To
aid in the realization of these goals, an ideal theranostic
nanocarrier should have excellent biocompatibility, good
loading efficiency, therapeutic shielding capacity, and tar-
geting capability and be amenable to multimodal contrast
agent modification. In many ways, lipoprotein-inspired na-
noparticles can address these goals and are a promising
platform for theranostic cancer nanomedicine.
Lipoproteins, Nature's Nanoparticles
Anever-increasingarsenalofdiversenanoparticlesexistsfor
potential cancer treatment. Validating how these behave
with regards to biocompatibility and loading ability is a
considerable undertaking that will continue for many years to
come. Althoughmanyofthese nanoparticleshave beendevel-
oped in the past 20 years, one notable exception is the
lipoprotein class of nanoparticles, which are naturally present
in most metazoan species and are essential in humans to
control lipid metabolism.
1 These endogenous nanoparticles
are utilized in organisms to transport hydrophobic cholesterol
and triglycerides to cells through the circulatory system. The
human endogenous lipoprotein system consists of several
types of lipoprotein nanoparticles that have varying structure
andfunction,differentiatedbytheirhydrodynamicsizeandthe
apolipoprotein(s) bound on their surfaces. The properties of
these different lipoproteins are summarized in Table 1. The
amphiphilic natureof thephospholipid helpsmaintainthe lipid
emulsion in aqueous solution, while the protein stabilizes the
emulsion.Thelipoproteinnanoparticlefieldhasbenefitedfrom
extensive history of basic discoveries stemming from research
in cholesterol metabolism. Some of those discoveries overlap
withthelipoproteinbreakthroughsrelevanttocancershownin
Figure 1, along with the significant theranostic advances.
2 7
Lipoproteins are ideal for the delivery of cancer drug and
imaging agents since they are able to circulate in the blood-
stream for a significant amount of time,
8 the hydrophobic
core facilitates the incorporation of poorly soluble drugs or
imaging agents, and they are highly amenable to bioconju-
gation.Thestructuralaspectsoflipoproteinsmayalsoplaya
critical role in their utility. Studies have shown that the
extracellular matrix of some cancer tumors may impede
the diffusion of nanoparticles due to the presence of col-
lagen fibrils.
9 Electron microscopy measurements have
shown the opening between these spaces to be less
than 40 nm, a distance which may hinder the penetration
of larger nanoparticles. This size range is difficult for
TABLE 1. Characteristics of Four Classes of Lipoproteins
a
surface component (mol %) core lipids (mol %)
diameter (nm) protein components protein phospholipid cholesterol cholesterol ester triglycerides
chylomicron 75 1200 ApoB-48 2 63 35 5 95
VLDL 30 80 ApoB-100 2 55 43 24 76
LDL 18 25 ApoB-100 2 58 42 19 81
HDL 5 12 ApoA-I, A-II, E, C 2 72 23 82 18
aAdapted with permission from Reference 59.
FIGURE 1. Key discoveries and theranostic advances in lipoprotein
cancer research.Vol. 44, No. 10 ’ 2011 ’ 1105–1113 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 1107
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phospholipid-based nanoparticles due to the destabilizing
effects of increasing lipid curvature. As lipid curvature in-
creases,sotoodoesthehydrophobicsurfaceexposedtothe
water. Lipoproteins are able to surmount this instability by
intercalating amphipathic R-helical proteins between the
phospholipids. Since low-density (LDL) and high-density
lipoproteins (HDL) are the only lipoproteins with diameters
less than 40 nm, we will focus our discussion on these two
classes of lipoproteins as they relate to cancer.
Transforming Lipoproteins into Versatile
Nanoparticles
There are three strategies to modify lipoproteins with ima-
ging or drug agents (Figure 2). These are covalent modifica-
tionofthephospholipidorprotein,intercalationoftheagent
into the phospholipid shell, and encapsulation of the agent
in the nanoparticle core through the reconstitution techni-
que.Loadinganagentataspecificsiteonthenanoparticleis
dependent on the method of incorporation as well as the
chemical nature of the molecule.
Surface Loading. Surface loading involves noncovalent
intercalation of the agent within the surface of the lipopro-
tein. Weak interactions including van der Waals forces
govern the degree of intercalation of the agent into the
particle surface. Agents that intercalate have a level of amphi-
philicity that allows its structure to be partially buried in the
surfaceofthelipoproteinleavingthehydrophilicfacepartially
exposed to the aqueous environment for hydrogen bonding
or ionic interactions. The balance between these forces influ-
ences the loading efficiency and stability. This strategy has
been used in used in combination with the cholate dialysis
technique to make drug loading lipoprotein nanoparticles.
10
Covalent Modification. Covalent modification of the lipo-
protein involves conjugating the therapeutic or imaging agent
to the surface of the apolipoprotein or onto the phospholipid
headgroup. Typical amino acids that are used for conjugation
include the lysine, arginine, tyrosine, and cysteine residues.
11
In addition to the surface protein or peptides, covalent mod-
ification can also be made on phospholipid headgroups.
11
CoreLoadingthroughReconstitution.Hydrophobicmo-
lecules can also be encapsulated into the nanoparticle core.
Generally, this involves exchanging the lipoprotein core
lipids with the desired hydrophobic molecule through lyo-
philization and organic extraction.
12 Another strategy in-
volves synthesizing the lipoprotein-like nanoparticle from
its component parts through methods such as cosonication
or cholate dialysis.
13
LDL: The Prototypic Lipoprotein for Cancer
Theranostics
Cholesterol is one of several hydrophobic molecules trans-
ported by lipoproteins. In the body, it functions as an
essential component of the plasma membrane and regu-
lates the fluidity of the lipid bilayer. Cholesterol is derived
through dietary sources or de novo biogenesis. As early as
1930, it was noted that patients with leukemia also had a
greaterchanceofhavinghypocholesterolemia.
14Laterstud-
ies showed that the hypocholesterolemia may be due to
increased LDLR presentation in the malignancy.
15 This ob-
servation has also been made for other cancer types.
16
LDL labeled with radiotracers has been used by investiga-
tors for over 20 years to image and characterize LDL tumor
accumulation within animals. Iodine-131 (
131I), iodine-125
(
125I), and technetium-99m (
99mTc) have been the most
commonly used radiolabels for in vivo imaging. Radioactive
iodine monochloride or reductive coupling of [
99mTc]
pertechnetate using sodium dithionite was used for covalent
modification of the protein. Studies with
99mTc-conjugated
LDLinB16melanoma-bearingmiceshowed accumulation in
the tumor after 18 h (Figure 3a).
17 While the gamma camera
usedtocapturetheaccumulationoftheradiolabeledLDLwas
FIGURE 2. Examples of drugs, imaging agents, and targeting ligands
incorporated into different locations of lipoprotein-like nanoparticles.1108 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 1105–1113 ’ 2011 ’ Vol. 44, No. 10
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poor in resolution, it provided a glimpse in real-time of the
distribution of LDL within the host. In addition to gamma
imaging,otherimagingmodalitiesandprobeshavealsobeen
used to observe other pathological situations. The effect of
liver LDL uptake in normal and hypocholesterolemic rabbits
was imaged by PET and gamma scintigraphy using gallium-
68 and indium-111, respectively.
18 These metals were at-
tached to LDL using a bifunctional metal chelator, diethylene
triamine pentaacetic acid (DTPA) anhydride, which was cova-
lently attached to apoB-100. While cancer was not the focus
of these studies, these techniques can be applied to the
imaging of neoplastic malignancies.
LDL has also been used as a nanocarrier for magnetic
resonance imaging contrast agents. Using a modified-DTPA
molecule originally synthesized by Jasanada et al.,
19 our
group chelated gadolinium (Gd) and intercalated the com-
plexintothelipidlayerofLDL.
20Throughthisprocedure,we
were able to insert 180 molecules of Gd onto the surface of
the particle. While the relaxivity of the construct on a per Gd
basis was negligibly greater than free gadolinium, a clear
demarcation of the tumor area could be observed upon
injection into tumor-bearing mice over a period of 24 48 h
(Figure 3b). Building on this work, Crich et al. substituted
DTPA with another Gd chelator named AAZTAC17, which
features enhanced relaxivity due to water molecule coordi-
nation to the Gd ion.
21 They found that this complex can be
stably incorporated into LDL and had a 2.5-fold enhance-
ment over the free Gd complex.
LDL nanoparticles have long been used for optical ima-
ging. Fluorescent probes have been incorporated into lipo-
proteins to study their function.
12 Our laboratory has been
interestedinusingopticaltechniquestoimagetheuptakeof
LDL within tumors (Figure 3c). Light penetration is a concern
with respect to optical imaging through tissues. To meet this
challenge, we developed a series of near-infrared probes
that were suitable for in vivo imaging.
22 24
To extend the applicability of LDL for the diagnostic
imaging of tumors, we asked whether LDL could be used
asacarrierfor(CT)contrastagentsthroughtheincorporation
of polyiodinated triglyceride (ITG) molecules.
25 ITG-loaded
LDL was taken up by HepG2 cells and showed enhanced
contrast compared with the cells alone and was inhibited by
the addition of LDL in excess (Figure 3d).
Endogenous LDL is able to transport an impressive number
of hydrophobic molecules in each particle. Estimates of this
number range from 1200 to 1300 cholesterol esters and
250 300 triglycerides.
26 This efficient loading of molecules
has driven interest in discovering whether drug delivery
vehiclescanbeconstructed thatmimictheseproperties.There
have been many reports of antineoplastic drugs that have
been incorporated into LDL for cancer therapy.
27 While the
drugscapableofbeingaccommodatedwithinLDLarediverse,
itisgenerallyassumedthathydrophobiccompoundspartition
more favorably to the LDL core and amphipathic compounds
tend to remain closer to the surface of LDL through less stable
interactions. Photodynamic therapy (PDT) agents have also
been loaded into LDL. In studying the use of porphyrin photo-
sensitizers for cancer therapy, it was noticed that porphyrins
had a propensity to associate with serum lipoproteins.
28
Furthermore, it was concluded that the tumor localization
properties of the porphyrin might also be influenced by
this interaction. The incorporation of phthalocyanines,
22
benzoporphyrins,
29 and tetraphenylporphines
30 (TPP) have
been reported. Our group has also focused on incorporating
photosensitizers within LDL particles through core-loading
reconstitution, which we predicted would improve the incor-
porationyieldandserumstabilityofthephotosensitizer.Using
thisstrategy,wehavesuccessfullyincorporatedlipid-anchored
NIR-active photosensitizers tetra-t-butyl silicon phthalo-
cyanine,
22 naphthalocyanine,
23 and pyropheophorbide.
31
LDL Rerouting: Expanding the Horizon of
Lipoprotein Cancer Targeting
One of the challenges of using LDLR as a target for cancer
theranostics is that the strategy is limited to cancers where
the receptor is highly expressed. For situations where the
FIGURE 3. (a) Gamma scintigraphy image of mouse bearing B-16
melanoma tumor upon uptake of
99mTc-labeled LDL (ref 17). (b) Mag-
neticresonanceimagingofmousexenograft(ref20).(c)Opticalimaging
of cancer tumor. (d) Demonstrated uptake of LDL loaded with CT
contrastinHepG2cancercells(ref25).Panelsa,b,anddarereproduced
with permission from the corresponding references.Vol. 44, No. 10 ’ 2011 ’ 1105–1113 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 1109
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LDLR is not highly expressed, a method for targeting LDL
nanoparticles to other cancer receptors iswarranted and will
expand the purview of all lipoprotein-based nanoparticles.
Remarkably, nature has already devised such a strategy as
demonstrated through the generation of oxidized LDL in
atherosclerosis. The oxidation of native LDL apolipoproteins
leads to a change in uptake from LDLR to receptors involved
in foam cell generation, which is a major factor in athero-
sclerosis. Bijsterbosch et al. showed that a similar strategy of
protein modification through reductive lactosamination was
able to increase the binding of LDL to Kupffer and parench-
ymal cells in the liver.
32 To extend this approach, our labora-
tory developed a general method for rerouting LDL
nanoparticles to other cancer targets (Figure 4a). The princi-
ple of the technique involves modifying a portion of the 225
exposedlysineresiduesthatexistonthehighlybasicdomain
on the apolipoprotein; 53 lysine residues have a pKa of 8.9
due to their local environment, which makes them highly
amenable to modification.
33 Modification of 20% of the side
chain ε-amino groups on lysine residues through alkylation
abolished the binding of LDL nanoparticles to the LDLR.
33
This phenomenon removes the native targeting of the LDL
nanoparticlewhileatthesametimeincreasingitsinteraction
with other cancer targets.
34 Using the folate receptor (FR)
as a cancer target, we modified the lysines with folate on
drug-loadedLDLnanoparticles,therebyreroutingtheparticle
from its endogenous receptor to the FR (Figure 4b). Further-
more, this application of tumor targeting has also been
shown to be extendable to HDL nanoparticles (Figure 4c).
35
HDL: The Smallest Lipoprotein
Properties and Advantages of Using HDL. In contrast to
the LDL, HDL forms smaller lipid nanoparticles (5 12 nm)
stabilized by the interactions of surface apolipoprotein A-1
(ApoA-1) proteins. This 243 amino acid protein adopts an
amphipathic R-helix structure and interacts with phospholi-
pids to generate discoidal or spherical structures depending
onthestoichiometryofthecomponents.
36Structuralstudies
on each of these forms of HDL have shown that discoidal
HDL is comprised of two ApoA-1 proteins per particle ar-
ranged in a belt-like structure around a bilayer of lipids. In
contrast, spherical HDL has been shown to contain two to
three ApoA-1 proteins arranged to form a trefoil structure
around the spherical emulsion.
36
Selective Uptake of Cholesterol Esters. Functionally, HDL
is responsible for facilitating transport of cholesterol from
tissues back to the liver for catabolism through a process
known as reverse cholesterol transport. It also delivers cho-
lesterol esters to steroidogenic tissues. The specific receptor
involved with HDL cholesterol uptake was discovered to be
thescavengerreceptorclassBtypeI(SR-BI) throughmolecular
cloning and pharmacological techniques.
2 Transport of CE
across the cell membrane was found to be mediated through
a nonendocytic pathway. This mechanism, referred to as
selective uptake, is thought to occur by a process in which a
hydrophobicchannelformsinSR-BIthatallowsforthetransfer
of core molecules across the membrane into the cell.
37
SR-BI and Cancer. There is mounting evidence that HDL
may also be a source of cholesterol in some malignancies.
HDL cholesterol levels were found to be lower in cancer
patients when compared with age- and sex-matched non-
cancer patients.
38 In humans, HDL has a role in cholesterol
effluxtocells. Similar toLDL,thisobserveddecreaseinserum
HDL might be a result of increased SR-BI receptor expression
on cancer cells, which shifts the serum HDL cholesterol levels
to a hypocholesterolemic state. In support of this view,
increased SR-BI expression has been reported in cancer cell
lines including prostate adenocarcinoma,
39 cervical
carcinoma,
40 breast cancer (MCF-7/HBL-100),
41 lung cancer
cell lines,
42 and hepatoma cell lines (HepG2 and HUH-7).
43
HDLasNanocarriersforTheranosticAgents.Oneofthe
first groups to systematically study the usage of HDL as a
nanocarrier for therapeutics was the Van Berkel laboratory.
FIGURE 4. (a) Schematic diagram showing the process of rerouting
lipoproteins to new cancer targets. (b) Whole body fluorescence image
showing folate-modified LDL uptake in FR-positive and negative cell
lines (ref 24). (c) Rerouting of HDL nanoparticles from SR-BI to the FR
(ref 35). Panels b and c are reproduced with permission from their
corresponding references.1110 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 1105–1113 ’ 2011 ’ Vol. 44, No. 10
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They found that lipophilic antiviral-analogs dioleyl iodo-
deoxyuridine and 9-(2-phosphonylmethoxyethyl)adenine
could be incorporated and delivered to liver cells.
44 Other
groups have also investigated the usage of HDL as a nano-
carrier for chemotherapeutics. Lacko et al. studied the use of
paclitaxel-loaded HDL particles on cancer cells and found
the IC50 to be 5 20 times lower than that of the free drug.
13
As a promising avenue of research, we designed a dual
function theranostic probe, bacteriochlorin e6 bisoleate,
whichcanbeeasilyincorporatedintoHDL(Figure5a).
40This
fluorescent photosensitizer can be tracked in vivo through
NIR fluorescence imaging and can be activated to generate
singlet oxygen upon light irradiation. Using fluorophore-
loaded HDL, we were also able to monitor the uptake of
the fluorescent payload over time using the dorsal skinfold
window chamber technique, which allows for monitoring of
nanoparticle tumor penetration with high spatial and tem-
poral resolution (Figure 5b).
HDL-Inspired Peptide-Phospholipid Scaffold
Nanoparticles
While HDL represents a useful agent for the delivery of
therapeutic and imaging agents to tumor cells, we foresee
several challenges on the road to clinical application. One in
particular is the source of apolipoproteins. While recombi-
nant ApoA-1 has been made in bacterial expression sys-
tems, there are challenges relating to purity and quantity
that remain to be overcome.
45 Isolation of ApoA-1 using
methods such as ultracentrifugation or delipidation proce-
dures appears to be the most common but has long
processing times. Finally, there are risks of pathogen con-
tamination in human blood-derived samples. Despite
these challenges, the purification of ApoA-1 from up to
700kgofhumanplasmaprecipitatehasbeenreported.
46The
procedure involves several steps to ensure that the
isolated protein is pathogen free. An alternative method to
circumvent these problems is to utilize synthetic peptide
analogs in the formulation process. One such peptide
is an 18-amino acid peptide abbreviated as 18A
(DWLKAFYDKVAEKLKEAF).
47 This peptide, while not having
any sequence homology to ApoA-1, retains some of the
characteristic features of the amphipathic protein. The pep-
tide adopts an R-helical conformation with charged groups
andhydrophobicsidechainspresentedonopposingfacesof
the peptide. Our laboratory has investigated the use of
amphipathic peptides as substitutes for ApoA-1 to circum-
vent some of the above-mentioned challenges. These syn-
thetic HDL-mimicking peptide phopholipid scaffold (HPPS)
nanoparticles showed promising capabilities as lipoprotein-
based nanoparticles through their morphological similari-
ties to HDL-like particles prepared from apolipoproteins
isolated from human sources (Figure 6a).
36 By taking ad-
vantageoftheirsmallsizeandmodifiablesurfacechemistry,
itispossibletoconjugateepidermalgrowthfactor(EGF)onto
the surface of these particles and direct them to cancer cells
expressing the EGF receptor.
48,49
Using Nature's Key To Open the Door for
Intracellular Delivery
Asdiscussedintheprevioussection,SR-BIhasbeenfoundto
be expressed in various types of cancer cells. Targeting the
SR-BI receptor for delivery of cancer theranostics warrants
further research. While the level of SR-BI expression on
cancer cellswill factor into the utility of this receptor for drug
targeting, it is the mode of uptake that may have implica-
tions for lipoprotein-mediated delivery of theranostic
agents. Althoughthe exact mechanismof howhydrophobic
moleculesencapsulatedinHDLareinternalizedviatheSR-BI
isstillasubjectofcontinuedresearch,thegeneralconsensus
is that this transport is mediated through a nonendocytic
mechanism. Our group demonstrated that this mechanism
of delivery can also be achieved with HPPS nanoparticles.
50
By incorporation of 1,10-dioctadecyl-3,3,30,30-tetramethylin-
dotricarbocyanineiodidebisoleate(DIRBOA)ordioleylfluor-
escein(FluoBOA)intothecoreofHPPS,uptakewasobserved
to be distributed homogeneously throughout the cell
FIGURE 5. (a) Optical imaging of a SR-BI expressing cancer tumor using
HDL nanoparticles loaded with NIR fluorescent photosensitizer bacter-
iochlorine6bisoleate(ref40).(b)Fluorophore-loadedHDL(red)showing
distribution to GFP-expressing tumor (green) through the bloodstream
(cyan). Figure 5Ais reproduced with permissionfrom the corresponding
reference.Vol. 44, No. 10 ’ 2011 ’ 1105–1113 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 1111
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interior, an indication of a nonendocytic uptake mechanism
(Figure 6b,c). Further evidence for this was provided as
incorporation of fluorescently labeled phospholipid into
HPPS led to an uncoupling of the surface and the core
fluorescence upon cell uptake. In contrast to the pattern of
DIRBOA distribution, the fluorophore-labeled phospholipid
remained on the cell membrane, indicating that internaliza-
tion of the entire particle did not occur. A similar pattern of
phospholipid core dissociation was also observed in a
F€ orster resonance energy transfer study using quantum
dot core-loaded HDL.
51 This ability to bypass the endosome
may show improved therapeutic efficacy in drugs that are
active within the cytosol. Recently, we studied the utility of
this nanocarrier in delivering two different types of thera-
peuticstocancercells.
52Paclitaxeloleate,amitoticinhibitor,
has been delivered to tumors using HPPS. Administration of
the nanoparticle to SR-BI expressing cancer tumors led to a
decrease in tumor size when compared with the vehicle
control. Furthermore, toxicity was not observed in tumors
that do not express the SR-BI. This indicated that HPPS is
successful in limiting the toxicity to cells that express SR-BI
(Figure 6d). While this formulation would only be useful in
tumors where the SR-BI expression is higher than in normal
tissues, the significance of these findings lies in the delivery
ofagentsthathaveanadditionallevelofspecificityandmay
benefit from escaping endosomal trapping. Examples of
such agents include siRNA, which only targets genes ex-
pressed in cancer cells, and photosensitizers, which are
known to be more efficacious against intracellular orga-
nelles.UsingHPPSloadedwithcholesterol siRNA,wefound
that delivery of this agent to the cell appeared to be
through a nonendocytic mechanism (Figure 6e).
53 This
uptake pattern was visibly different from the uptake of
cholesterol siRNA alone or loaded within a common trans-
fectionagentsuchaslipofectamine.Proteinstargetedbythe
siRNA showed a decrease in the expression levels in HPPS
chol siRNA treated cells versus free chol siRNA. While the
exact mechanism of delivery of cholesterol siRNA from
HPPSisnotfullyunderstood,wespeculate thatthismechan-
ism also involves SR-BI.
Future Outlook
Lipoprotein-based nanoparticles have been loaded with a
diverse range of therapeutic and imaging agents for cancer.
Application of lipoprotein-based nanoparticles should not
simply be limited by this disease state. In fact, lipoprotein-
mediated delivery of antifungals
54 and antivirals
55 has also
been reported.Another veinof researchis theapplication of
lipoproteins to imaging atherosclerotic plaques. The crea-
tion of nanocrystal-core lipoprotein nanoparticles using
inorganic molecules has extended the application of lipo-
proteinnanoparticlesindiagnosticimaging.
56Thistrendwill
continue as more imaging techniques such as surface-en-
hanced Raman spectroscopy are applied.
57 In addition,
novel discoveries at the interface between lipoproteins
andDNAmolecularbeaconshavealsobeenmade,allowing
for the programmable aggregation of lipoprotein nano-
particles.
58 Finally, over the last several years the landscape
of ApoA-1 clinical testing has changed dramatically. In
the past decade, there have been several clinical studies
determining the safety and efficacy of wild-type ApoA-1
and its derivatives for cardiovascular applications. The
proven safety of such compounds and the rest of the
components comprising the lipoprotein nanoparticle sets
thestageforclinicaltestingofsimilarnanocarriersforcancer
treatment.
FIGURE 6. (a) Structural comparison between discoidal and spherical
structure generated using ApoA-1 (first row) (ref 36) or 4F phospholipid
(second row) (ref 49). (b) Schematic diagram illustrating transfer of HPPS
core components to cells through a nonendocytic pathway (ref 49).
(c) Cytosolic delivery of HPPS (ref 50). (d) Drug shielding and targeting of
paclitaxel oleate-loaded HPPS. (e) Delivery of bcl-2 targeting siRNA to
cancer cells imaged using confocal microscopy along with analysis of
protein expression in treated versus untreated groups (ref 53). Panels a,
b, c and e are reproduced with permission from their corresponding
references.1112 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 1105–1113 ’ 2011 ’ Vol. 44, No. 10
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